AI Drug Rentosertib Shows Biological Age Reversal in Trial
Six AI aging clocks found lower biological age in IPF patients on AI-designed drug rentosertib, but effects in healthy people remain untested.
Artificial intelligence is reshaping how discovery happens across chemistry, biology, physics, and energy research. Rather than replacing scientists, machine learning models are becoming powerful collaborators—sifting through molecular libraries, predicting protein structures, simulating physical systems, and identifying patterns in datasets too large or complex for traditional analysis. This shift is compressing timelines that once spanned years into months or weeks, particularly in fields like drug discovery, materials science, and clean energy research.
Why now? Three forces are converging: dramatic improvements in generative and predictive AI models, the availability of specialized computing hardware built for scientific workloads, and growing pressure from industry and governments to accelerate breakthroughs in medicine, energy security, and advanced computing. Pharmaceutical companies are racing to embed AI systems directly into drug discovery pipelines, while national labs and tech firms are exploring how quantum computing and machine learning together might unlock advances in areas like fusion energy. At the same time, the computational demands of these AI systems are prompting a closer look at energy consumption—creating both challenges and unexpected opportunities for clean power innovation.
Readers of this hub will find ongoing coverage of how major pharmaceutical and technology companies are deploying AI platforms for drug and materials discovery, how quantum computing is being paired with machine learning to tackle previously intractable scientific problems, and how the energy costs of AI infrastructure are influencing the broader clean energy landscape. Expect reporting on new partnerships, deployed systems, research breakthroughs, and the infrastructure debates shaping the future of scientific discovery—tracking both the promise and the practical trade-offs of AI-accelerated science.
Six AI aging clocks found lower biological age in IPF patients on AI-designed drug rentosertib, but effects in healthy people remain untested.
BioCryst is using Orladeyo profits and its $700M Astria buy to become a rare-disease acquirer, closing internal drug discovery in Birmingham.
UK venture capital rebounds via biotech and software, as AI drug discovery and controversial CRISPR embryo editing startups draw fresh funding.
Anthropic's Claude AI designed protein binders that worked against 14 of 15 disease targets, tested in lab experiments.
Buffalo's Empire AI system and a $5B federal push highlight AI's growing role in cancer research and scientific discovery.
AI, automated chemistry, and quantum-materials breakthroughs are together speeding up how new materials are discovered and understood.
AI is transforming cancer research, disease prediction, and virus design, while raising new biosecurity concerns and drawing $5B in federal funding.
Novo Nordisk and AWS launched an AI drug discovery hub as AI reshapes bioinformatics, biolabs, and protein design across the industry.
New AI tool Aladynoulli reportedly predicts risk for 348 diseases, part of a wider surge in AI-driven scientific discovery and funding.
New reports show AI tools are speeding scientific discovery in fusion, math, and biology while research diversity may be narrowing.
Anthropic says Claude AI designed proteins that scientists validated in lab tests, amid wider AI science funding and biosecurity concerns.
AI drug discovery draws billions as Anthropic, Bristol Myers, Recursion and Generate Biomedicines bet big on faster cures.
Stanford and Arc Institute used AI to design new viruses, sparking excitement over science and fears about biosecurity risks.
AI-driven biotech startups like Accipiter Bio and Tahoe Therapeutics raise fresh funding as the industry's geography and priorities shift.
AI-driven drug discovery is expanding fast, from pulmonary fibrosis trials to Nvidia deals and Anthropic's new pharma push.
Tahoe Therapeutics raised $30M to build AI models of living cells for cancer drug discovery, per Forbes and other reports.
A company gene-edited two beagle puppies to lack a major allergen, part of a wider surge in CRISPR breakthroughs and safety debates.
AI-driven drug discovery is drawing IPOs, pharma partnerships, and Nvidia hardware deals as generative biology reshapes biotech.
Phylo and Chugai's AI platform deal highlights a broader surge in AI-driven drug discovery investment and technology in 2026.
AI is transforming research, diagnostics, funding and education, from UVA labs to Bristol Myers' Nvidia deal and Trump's science overhaul.
Fusion energy advances via GA hardware, UK magnets, quantum-AI tritium research, and new funding and facilities across the US and UK.
A fusion firm reportedly raised a billion dollars as quantum computing and materials science advances tackle fusion's toughest hurdles.
Accipiter Bio raised $10.5M more from existing investors to speed AI-designed protein drug development and expand its pipeline.
GSK signs a deal worth up to $110M with Relation Therapeutics to build AI models and cellular datasets for new drug discovery.
AI-designed drugs are entering clinical trials as Anthropic, Nvidia, Bristol Myers Squibb, and Generate Biomedicines drive a pharma R&D shift.
Anthropic, Nvidia, Bristol Myers Squibb and Generate Biomedicines fuel a rapid AI-driven transformation of drug discovery and development.
Nuclear fusion funding hit a record $4.5B this year, as materials science and IBM's quantum computing tackle tritium fuel and reaction efficiency.
AI drug discovery gains momentum as MindWalk, Anthropic, Bristol Myers, and Generate Biomedicines pursue faster, tech-driven pharmaceutical R&D.
IBM, Oak Ridge and Cleveland Clinic used quantum computing and AI to model tritium production, tackling a key barrier to nuclear fusion energy.
Bristol Myers Squibb is buying Nvidia's newest AI computing system to accelerate drug discovery, as rivals in the U.S. and China race ahead.